Skip to main content

NewAmsterdam Pharma Co N.V.

NAMS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001936258

In the last 90 days, NewAmsterdam Pharma Co N.V. insiders filed 1 open-market purchase and 4 sales; 194 institutions reported holding it in 13F filings for Q2 2026, worth $4.13B in total; 3 superinvestors hold it, including Viking Global Investors and Maverick Capital.

Other share classesNAMSW

Q1 2023 vs. Q4 2022

How the institutions holding NewAmsterdam Pharma Co N.V. changed between Q4 2022 and Q1 2023.

All holders in Q1 2023All holders in Q4 2022

13F holders of NAMS: Q4 2022 compared with Q1 2023
MeasureQ4 2022Q1 2023Change
Holders1419+5
Shares33.5M33.3M−169.9K (−0.5%)
Value$362.2M$444.9M+$82.6M (+22.8%)

New holders (8)

Institutions that held NewAmsterdam Pharma Co N.V. at the end of Q1 2023 but not at the end of Q4 2022.

Institutions new to NAMS in Q1 2023
InstitutionSharesValue% of portfolio
Parkman Healthcare Partners LLC115,000$1.52M0.33%
Millennium Management LLC55,633$748.0K0.00%
Eversept Partners, LP45,856$608.1K0.05%
Schonfeld Strategic Advisors LLC30,100$399.1K0.00%
Geode Capital Management, LLC18,559$249.4K0.00%
Wolverine Asset Management LLC4,819$63.9K0.00%
Morgan Stanley503$6.67K0.00%
Atticus Wealth Management, LLC166$2.20K0.00%

Sold out (3)

Institutions that held NewAmsterdam Pharma Co N.V. at the end of Q4 2022 and filed for Q1 2023 without it.

Institutions that sold out of NAMS in Q1 2023
InstitutionShares, Q4 2022Value, Q4 2022
Janus Henderson Group PLC563,119$5.33M
Alyeska Investment Group, L.P.200,000$1.89M
Tower Research Capital LLC (TRC)88$1.00K